Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data
Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Immune checkpoint inhibitors (ICIs) are increasingly used in patients with gastrointestinal cancer (GIC). However, ICI‐associated adverse event (AE) profiles in GIC remain poorly characterized, and whether AE incidence is associated with clinical outcomes is unclear.
Jing Lei, Yi-Yi Yu, Qing Liu et al.· Cancer Medicine· 1 citation
Materials and methods. A literature review was conducted based on scientific publications investigating imatinib and nilotinib derivatives. Structural modification strategies, including aromatic and heterocyclic fragment modification, halogen and trifluoromethyl (CF₃) substitution, sp³-rich fragment introduction, hybri...
M. Mamajonova· Natural Sciences in the Mode...· 0 citations
the importance of clinicopathological characterization and biomarker discovery. Emerging pharmacological approaches, including EZH2 inhibition, PARP-directed combination therapies, and natural product-based therapies such as (+)-PTC, may restore therapeutic sensitivity and ultimately contribute to precision oncology an...
Pulak Kar, D. Colangelo, M. Kumar et al.· Frontiers in Pharmacology· 0 citations
Targeted kinase inhibitors have shown statistically and clinically significant improvements in platelet response among patients with primary ITP, supporting their utility as effective targeted therapeutic strategies. We evaluated the efficacy and safety of Bruton tyrosine kinase (BTK) and spleen tyrosine kinase (SYK) i...
Ayah Abulehia, R. B. Alshareef, Shorouq Khateeb et al.· eJHaem· 0 citations
To evaluate the efficacy and safety of PD‐1/PD‐L1 inhibitors plus small‐molecule anti‐angiogenic drugs (apatinib, anlotinib and famitinib) for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).
Rong-Yi Hu, Tie-Bin Li, Zi-Man Luo et al.· Cancer Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.